Pre-Immunization and Immunotherapy in HIV(+) Patients IL

Country:
Israel

Docket No:
436313-001191

Publication Number:
284348

Patent Expiry:
01/11/2037

Claims Scope:

Allowed.  Issue fee paid.  Awaiting patent certificate. 

 

Sequence (and Gene) Agnostic Method Claims 

Two sequence-specific guides  

Two sequence-specific guide+backbone (corrected) 

  • Sequence agnostic method claim to CCR5 only, with a viral particle encoding a small RNA capable of inhibiting expression of CCR5  
  • Sequence agnostic method claim to HIV gene, with a viral particle encoding a small RNA capable of inhibiting expression of at least one HIV gene  
  • Two sequences with 80% identity to SIN 2, & 108 (mir21Vif, and corrected sequence mir185 Tat, any order) guide + backbone 
  • Two of three sequences with 80% identity to SIN 1, 2 and 108 (mir30 CCR5, mir21Vif, and corrected mir185Tat) 
  • Two of three sequences with 80% identity to SIN 97, 6 & & 7 (CCR5, Vif, and Tat, any order) guide only 
  • Compositions & methods (broadest method claims agnostic to pre-immunized state; dependent claims include pre-immunization)